Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
113 Leser
Artikel bewerten:
(0)

Lexogen and Bluebee Partner to Bring the SLAMseq Metabolic RNA Sequencing Data Analysis Pipeline to the Users

RIJSWIJK, Netherlands and VIENNA, November 10, 2017 /PRNewswire/ --

Bluebee, a company driving genomic data-driven medicine, and Lexogen a company enabling the analysisof the complete transcriptome, announce the successful integration of the SLAMdunk pipeline on Bluebee's private cloud-based platform, making it available to analyze data generated by every user of the SLAMseq Metabolic RNA Labeling Kit from Lexogen.

The family of SLAMseq Metabolic RNA labeling kits was successfully released in September this year accompanying the publication of the SLAMseq method in the Nature Methods journal (DOI:10.1038/nmeth.4435). The method is based on S4U labeling of RNA in cell cultures, alkylation of RNA with iodoacetamide, and consequent introduction of T to C mutations in cDNA. By just adding two extra steps to RNA-Seq workflows, the SLAMseq approach provides a unique tool for the study of RNA metabolism and measure nascent RNA expression. Synthesis and degradation can be monitored transcriptome-wide by analyzing nascent and steady-state RNA levels in the same cell extract.

A dedicated SLAMseq data analysis pipeline SLAMdunk has been collaboratively developed by scientists from the IMP, MFPL and IMBA research institutes in Vienna, Austria and integrated on the Bluebee platform.

"At Bluebee we are helping to drive research in gene expression, not only by providing standardized execution and reducing the data analysis burden but by helping people get more knowledge and insights from their genomic data." said Hans Cobben, CEO of Bluebee.

The SLAMdunk data analysis pipeline consists of 5 major steps. In themapstep reads are aligned to a reference genome, and in thefilterstep unique alignments satisfying certain quality criteria are retained. In the snpstep variants are called and excluded from further analysis. In the countstep, the T to C conversion rate and the ratio of nascent RNA is determined. The alleyoop step then produces summary statistics, a PCA for all samples, and several conversion rate plots (read based, UTR based, read position based).

Tobias Neumann (Zuber group at IMP), who co-developed the SLAMdunk pipeline together with Philipp Rescheneder (von Haeseler group at MFPL) explains: "Our goal for developing SLAMdunk was to provide a fully integrated data analysis pipeline that makes SLAMseq results readily accessible to bench scientists. The main challenges we had to overcome were the increased mismatch rate caused by T to C conversions and the lower sequence complexity of 3' UTRs which make it hard to place SLAMseq reads correctly on the reference genome. Combining tailored cutting-edge mapping algorithms, multimapper recovery methods and variant callers, we are now able to provide accurate and unbiased readouts of T to C conversions and nascent RNA ratios in a robust and reproducible manner."

"In collaboration with Bluebee we already offer complimentary data analysis to all QuantSeq 3'mRNA-Seq users thus providing full workflow to ensure highest quality results from the RNA-Seq experiment. Now all SLAMseq users will also have access to a secure, user-friendly and well-defined data analysis on Bluebee platform. " - Dalia Daujotyte, Head of Business Development at Lexogen.

About Bluebee

Bluebee offers a global bio-informatics platform to process, analyze, share and store genomics data.

With a private cloud service, Bluebee supports users in clinical diagnostics, therapeutics and research with advanced analytics for genomic data driven medicine.

Designed for cross-functional teams of clinicians and life science researchers the Bluebee platform effectively centralizes and manages genomics data processes and storage. Bluebee's multi-layered security is designed to meet both specific organizational and regulatory data protection requirements when analyzing and storing research or clinical grade data.

Local data processing is guaranteed via "Data Residency Control" in state-of-the-art data centres. The service is available across all major European countries and US cities, as well as in Canada and Asia Pacific.

http://www.bluebee.com/

About Lexogen

Lexogen is a transcriptomics and next generation sequencing company, focusing on the development of technologies for complete transcriptome sequencing. Its portfolio includes innovative molecular biology kits, software, and services for RNA-Seq.

To learn more, visit www.lexogen.com and follow @lexogen.

http://www.lexogen.com/

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.